- Moderna and Merck collaborated on a personalized mRNA cancer vaccine.
- The vaccine targets melanoma and has completed a Phase 3 trial.
Moderna and Merck reported their personalized mRNA cancer vaccine succeeded in a Phase 3 trial for melanoma. AI reportedly helped design the vaccine.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.